News

Cardiac amyloidosis (CA) frequently coexists with atrial fibrillation (AF), but the extent and impact of this relationship remain unclear. This study investigates…

AbstractTransthyretin (TTR) amyloid cardiomyopathy occurs when stable TTR, normally a 4-protein tetramer, becomes misfolded and aggregates to form amyloid fibrils…

NICE(UK): Acoramidis can be used, within its marketing authorisation, as an option to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in…

NEW ORLEANS—An artificial intelligence model trained to analyze electrocardiogram (ECG) images identified which patients had transthyretin-mediated amyloid…

Key TakeawaysTransthyretin amyloid cardiomyopathy is increasingly diagnosed in the US (~120,000 affected), particularly among older adults and men, and remains…

Tafamidis treatment was associated with a significant reduction in the risk of ischemic stroke in patients with transthyretin-mediated amyloid cardiomyopathy…

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

Neuropathy followed by heart damage points to hATTRA rare mutation in the TTR gene — mutations in which are the cause of hereditary transthyretin amyloidosis (hATTR…

LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX) announced today the completion of enrollment in its NEXICART-2 trial, a Phase 2 study evaluating CAR-T therapy NXC…

Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialKey PointsQuestion  Is long-term treatment with acoramidis in transthyretin amyloid…